[Incomplete and complete "fetal alcohol syndrome" in three children of an alcoholic mother].

H. Manzke,F. Grosse

1975-04-11

Abstract:

What problem does this paper attempt to address?

Targeted protein degrader development for cancer: advances, challenges, and opportunities

Yuan Fang,Shuhang Wang,Songzhe Han,Yizhou Zhao,Cunjing Yu,Huaqing Liu,Ning Li

DOI: https://doi.org/10.1016/j.tips.2023.03.003

IF: 17.638

2023-04-14

Trends in Pharmacological Sciences

Abstract:Anticancer-targeted therapies inhibit various kinases implicated in cancer and have been used in clinical settings for decades. However, many cancer-related targets are proteins without catalytic activity and are difficult to target using traditional occupancy-driven inhibitors. Targeted protein degradation (TPD) is an emerging therapeutic modality that has expanded the druggable proteome for cancer treatment. With the entry of new-generation immunomodulatory drugs (IMiDs), selective estrogen receptor degraders (SERDs), and proteolysis-targeting chimera (PROTAC) drugs into clinical trials, the field of TPD has seen explosive growth in the past 10 years. Several challenges remain that need to be tackled to increase successful clinical translation of TPD drugs. We present an overview of the global landscape of clinical trials of TPD drugs over the past decade and summarize the clinical profiles of new-generation TPD drugs. In addition, we highlight the challenges and opportunities for the development of effective TPD drugs for future successful clinical translation.

pharmacology & pharmacy
Advancing targeted protein degradation for cancer therapy

Brandon Dale,Meng Cheng,Kwang-Su Park,H. Ümit Kaniskan,Yue Xiong,Jian Jin

DOI: https://doi.org/10.1038/s41568-021-00365-x

IF: 78.5

2021-06-15

Nature Reviews Cancer

Abstract:The human proteome contains approximately 20,000 proteins, and it is estimated that more than 600 of them are functionally important for various types of cancers, including nearly 400 non-enzyme proteins that are challenging to target by traditional occupancy-driven pharmacology. Recent advances in the development of small-molecule degraders, including molecular glues and heterobifunctional degraders such as proteolysis-targeting chimeras (PROTACs), have made it possible to target many proteins that were previously considered undruggable. In particular, PROTACs form a ternary complex with a hijacked E3 ubiquitin ligase and a target protein, leading to polyubiquitination and degradation of the target protein. The broad applicability of this approach is facilitated by the flexibility of individual E3 ligases to recognize different substrates. The vast majority of the approximately 600 human E3 ligases have not been explored, thus presenting enormous opportunities to develop degraders that target oncoproteins with tissue, tumour and subcellular selectivity. In this Review, we first discuss the molecular basis of targeted protein degradation. We then offer a comprehensive account of the most promising degraders in development as cancer therapies to date. Lastly, we provide an overview of opportunities and challenges in this exciting field.

oncology
Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Hong‐Yi Zhao,Minhang Xin,San‐Qi Zhang

DOI: https://doi.org/10.1002/ddr.22026

2023-01-08

Drug Development Research

Abstract:Recent years have witnessed the rapid development of targeted protein degradation (TPD), especially proteolysis targeting chimeras. These degraders have manifested many advantages over small molecule inhibitors. To date, a huge number of degraders have been excavated against over 70 disease‐related targets. In particular, degraders against estrogen receptor and androgen receptor have crowded into phase II clinical trial. TPD technologies largely expand the scope of druggable targets, and provide powerful tools for addressing intractable problems that can not be tackled by traditional small molecule inhibitors. In this review, we mainly focus on the structures and biological activities of small molecule degraders as well as the elucidation of mechanisms of emerging TPD technologies. We also propose the challenges that exist in the TPD field at present.

pharmacology & pharmacy,chemistry, medicinal
Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Jin Li,Xinxin Chen,Aiping Lu,Chao Liang

DOI: https://doi.org/10.1016/j.xinn.2023.100413

2023-03-15

Abstract:Targeted protein degradation (TPD) is emerging as a strategy to overcome the limitations of traditional small-molecule inhibitors. Proteolysis-targeting chimera (PROTAC) technology can be used to target proteins by hijacking the ubiquitin-proteasome system. Conceptually, PROTAC aims to target the "undruggable" majority of proteins in the human proteome. Through constant exploration and optimization of PROTACs and the exploitation of other TPD strategies over two decades, TPD has expanded from theoretical studies to clinical strategies, with practical applications in oncological, immunological, and other diseases. In this review, we introduce the mechanisms, features, and molecular targets of orthodox PROTACs and summarize the PROTAC drugs under study as cancer therapeutics in clinical trials. We also discuss PROTAC derivatives and other TPD strategies, such as lysosome-targeting chimeras, autophagy-targeting chimeras, and molecular glue strategies. Collectively, the studies summarized herein support the full potential of TPD in the biomedical industry.
Recent advances in targeted protein degraders as potential therapeutic agents

Na Yang,Bo Kong,Zhaohong Zhu,Fei Huang,Liliang Zhang,Tao Lu,Yadong Chen,Yanmin Zhang,Yulei Jiang

DOI: https://doi.org/10.1007/s11030-023-10606-w

2023-02-16

Molecular Diversity

Abstract:Targeted protein degradation (TPD) technology has gradually become widespread in the past 20 years, which greatly boosts the development of disease treatment. Contrary to small inhibitors that act on protein kinases, transcription factors, ion channels, and other targets they can bind to, targeted protein degraders could target "undruggable targets" and overcome drug resistance through ubiquitin–proteasome pathway (UPP) and lysosome pathway. Nowadays, some bivalent degraders such as proteolysis-targeting chimeras (PROTACs) have aroused great interest in drug discovery, and some of them have successfully advanced into clinical trials. In this review, to better understand the mechanism of degraders, we elucidate the targeted protein degraders according to their action process, relying on the ubiquitin–proteasome system or lysosome pathway. Then, we briefly summarize the study of PROTACs employing different E3 ligases. Subsequently, the effect of protein of interest (POI) ligands, linker, and E3 ligands on PROTAC degradation activity is also discussed in detail. Other novel technologies based on UPP and lysosome pathway have been discussed in this paper such as in-cell click-formed proteolysis-targeting chimeras (CLIPTACs), molecular glues, Antibody-PROTACs (Ab-PROTACs), autophagy-targeting chimeras, and lysosome-targeting chimeras. Based on the introduction of these degradation technologies, we can clearly understand the action process and degradation mechanism of these approaches. From this perspective, it will be convenient to obtain the development status of these drugs, choose appropriate degradation methods to achieve better disease treatment and provide basis for future research and simultaneously distinguish the direction of future research efforts.

chemistry, multidisciplinary, medicinal, applied
Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes

Janarthanan Venkatesan,Dhanashree Murugan,Kalaiarasu Lakshminarayanan,Alexis R Smith,Harashkumar Vasanthakumari Thirumalaiswamy,Hariprasath Kandhasamy,Boutheina Zender,Guangrong Zheng,Loganathan Rangasamy

DOI: https://doi.org/10.1016/j.pharmthera.2024.108725

Abstract:Targeted protein degradation (TPD) has emerged as a prominent and vital strategy for therapeutic intervention of cancers and other diseases. One such approach involves the exploration of proteolysis targeting chimeras (PROTACs) for the selective elimination of disease-causing proteins through the innate ubiquitin-proteasome pathway. Due to the unprecedented achievements of various PROTAC molecules in clinical trials, researchers have moved towards other physiological protein degradation approaches for the targeted degradation of abnormal proteins, including lysosome-targeting chimeras (LYTACs), autophagy-targeting chimeras (AUTACs), autophagosome-tethering compounds (ATTECs), molecular glue degraders, and other derivatives for their precise mode of action. Despite numerous advantages, these molecules face challenges in solubility, permeability, bioavailability, and potential off-target or on-target off-tissue effects. Thus, an urgent need arises to direct the action of these degrader molecules specifically against cancer cells, leaving the proteins of non-cancerous cells intact. Recent advancements in TPD have led to innovative delivery methods that ensure the degraders are delivered in a cell- or tissue-specific manner to achieve cell/tissue-selective degradation of target proteins. Such receptor-specific active delivery or nano-based passive delivery of the PROTACs could be achieved by conjugating them with targeting ligands (antibodies, aptamers, peptides, or small molecule ligands) or nano-based carriers. These techniques help to achieve precise delivery of PROTAC payloads to the target sites. Notably, the successful entry of a Degrader Antibody Conjugate (DAC), ORM-5029, into a phase 1 clinical trial underscores the therapeutic potential of these conjugates, including LYTAC-antibody conjugates (LACs) and aptamer-based targeted protein degraders. Further, using bispecific antibody-based degraders (AbTACs) and delivering the PROTAC pre-fused with E3 ligases provides a solution for cell type-specific protein degradation. Here, we highlighted the current advancements and challenges associated with developing new tumour-specific protein degrader approaches and summarized their potential as single agents or combination therapeutics for cancer.
Targeted protein degradation in drug development: Recent advances and future challenges

Jian Song,Mingzheng Hu,Jun Zhou,Songbo Xie,Tianliang Li,Yan Li

DOI: https://doi.org/10.1016/j.ejmech.2023.115839

IF: 7.088

2023-09-28

European Journal of Medicinal Chemistry

Abstract:Targeted protein degradation (TPD) has emerged as a promising therapeutic approach with potential advantages over traditional occupancy-based inhibitors in terms of dosing, side effects and targeting "undruggable" proteins. Targeted degraders can theoretically bind any nook or cranny of targeted proteins to drive degradation. This offers convenience versus the small-molecule inhibitors that must function in a well-defined pocket. The degradation process depends mainly on two cell self-destruction mechanisms, namely the ubiquitin-proteasome system and the lysosomal degradation pathway. Various TPD strategies (e.g., proteolytic-targeting chimeras, molecular glues, lysosome-targeting chimeras, and autophagy-targeting chimeras) have been developed. These approaches hold great potential for targeting dysregulated proteins, potentially offering therapeutic benefits. In this article, we systematically review the mechanisms of various TPD strategies, potential applications to drug discovery, and recent advances. We also discuss the benefits and challenges associated with these TPD strategies, aiming to provide insight into the targeting of dysregulated proteins and facilitate their clinical applications.

chemistry, medicinal
Targeted protein degradation: advances in drug discovery and clinical practice

Guangcai Zhong,Xiaoyu Chang,Weilin Xie,Xiangxiang Zhou

DOI: https://doi.org/10.1038/s41392-024-02004-x

IF: 39.3

2024-11-06

Signal Transduction and Targeted Therapy

Abstract:Targeted protein degradation (TPD) represents a revolutionary therapeutic strategy in disease management, providing a stark contrast to traditional therapeutic approaches like small molecule inhibitors that primarily focus on inhibiting protein function. This advanced technology capitalizes on the cell's intrinsic proteolytic systems, including the proteasome and lysosomal pathways, to selectively eliminate disease-causing proteins. TPD not only enhances the efficacy of treatments but also expands the scope of protein degradation applications. Despite its considerable potential, TPD faces challenges related to the properties of the drugs and their rational design. This review thoroughly explores the mechanisms and clinical advancements of TPD, from its initial conceptualization to practical implementation, with a particular focus on proteolysis-targeting chimeras and molecular glues. In addition, the review delves into emerging technologies and methodologies aimed at addressing these challenges and enhancing therapeutic efficacy. We also discuss the significant clinical trials and highlight the promising therapeutic outcomes associated with TPD drugs, illustrating their potential to transform the treatment landscape. Furthermore, the review considers the benefits of combining TPD with other therapies to enhance overall treatment effectiveness and overcome drug resistance. The future directions of TPD applications are also explored, presenting an optimistic perspective on further innovations. By offering a comprehensive overview of the current innovations and the challenges faced, this review assesses the transformative potential of TPD in revolutionizing drug development and disease management, setting the stage for a new era in medical therapy.

biochemistry & molecular biology,cell biology
World Medical Association ;now more realistic' in dealing with problems.

S. Gilder

1972-11-18

Canadian Medical Association Journal

Abstract:
Hydrophobic tag-based protein degradation: Development, opportunity and challenge

Qindi He,Xiaofei Zhao,Donglin Wu,Siming Jia,Canlin Liu,Zitian Cheng,Fei Huang,Yadong Chen,Tao Lu,Shuai Lu

DOI: https://doi.org/10.1016/j.ejmech.2023.115741

IF: 7.088

2023-11-01

European Journal of Medicinal Chemistry

Abstract:Targeted protein degradation (TPD) has emerged as a promising approach for drug development, particularly for undruggable targets. TPD technology has also been instrumental in overcoming drug resistance. While some TPD molecules utilizing proteolysis-targeting chimera (PROTACs) or molecular glue strategies have been approved or evaluated in clinical trials, hydrophobic tag-based protein degradation (HyT-PD) has also gained significant attention as a tool for medicinal chemists. The increasing number of reported HyT-PD molecules possessing high efficiency in degrading protein and good pharmacokinetic (PK) properties, has further fueled interest in this approach. This review aims to present the design rationale, hydrophobic tags in use, and diverse mechanisms of action of HyT-PD. Additionally, the advantages and disadvantages of HyT-PD in protein degradation are discussed. This review may help inspire the development of more HyT-PDs with superior drug-like properties for clinical evaluation.

chemistry, medicinal
Novel approaches to targeted protein degradation technologies in drug discovery

Yu Xue,Andrew A Bolinger,Jia Zhou

DOI: https://doi.org/10.1080/17460441.2023.2187777

Abstract:Introduction: Target protein degradation (TPD) provides a novel therapeutic modality, other than inhibition, through the direct depletion of target proteins. Two primary human protein homeostasis mechanisms are exploited: the ubiquitin-proteasome system (UPS) and the lysosomal system. TPD technologies based on these two systems are progressing at an impressive pace. Areas covered: This review focuses on the TPD strategies based on UPS and lysosomal system, mainly classified into three types: Molecular Glue (MG), PROteolysis Targeting Chimera (PROTAC), and lysosome-mediated TPD. Starting with a brief background introduction of each strategy, exciting examples and perspectives on these novel approaches are provided. Expert opinion: MGs and PROTACs are two major UPS-based TPD strategies that have been extensively investigated in the past decade. Despite some clinical trials, several critical issues remain, among which is emphasized by the limitation of targets. Recently developed lysosomal system-based approaches provide alternative solutions for TPD beyond UPS' capability. The newly emerging novel approaches may partially address issues that have long plagued researchers, such as low potency, poor cell permeability, on-/off-target toxicity, and delivery efficiency. Comprehensive considerations for the rational design of protein degraders and continuous efforts to seek effective solutions are imperative to advance these strategies into clinical medications.
Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques

Siyu Chen,Jingliang Cui,Haiyan Chen,Bo Yu,Sihui Long

DOI: https://doi.org/10.1016/j.ejmech.2023.115911

2023-12-15

Abstract:Targeted protein degradation (TPD) is one of the key strategies of current targeted cancer therapy, and it can eliminate some of the root causes of cancer, and effectively avoid drug resistance caused by traditional drugs. Proteolysis targeting chimera (PROTAC) is a hot branch of the TPD strategy, and it has been shown to induce the degradation of target proteins by activating the inherent ubiquitin-proteasome system (UPS) in tumor cells. PROTACs have been developed for more than two decades, and some of them have been clinically evaluated. Although most of the proteins degraded by PROTACs are intracellular, degradation of some typical membrane proteins has also been reported, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), programmed death ligand 1 (PD-L1), and G-protein-coupled receptor (GPCR). In addition, some other effective membrane protein-degrading strategies have also emerged, such as antibody-based PROTAC (AbTAC), lysosome targeting chimera (LYTAC), molecular glue, and nanoparticle-based PROTAC (Nano-PROTAC). Herein, we discussed the advantages, disadvantages and potential applications of several important membrane protein degradation techniques. These techniques that we have summarized are insightful in paving the way for future development of more general strategies for membrane protein degradation.
Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Yufeng Xiao,Yaxia Yuan,Yi Liu,Zongtao Lin,Guangrong Zheng,Daohong Zhou,Dongwen Lv

DOI: https://doi.org/10.1021/acs.jmedchem.4c00723

IF: 8.039

2024-01-01

Journal of Medicinal Chemistry

Abstract:Targeted protein degradation (TPD), including the use of proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs) to degrade proteins, is an emerging strategy to develop novel therapies for cancer and beyond. PROTACs or MGDs function by inducing the proximity between an E3 ligase and a protein of interest (POI), leading to ubiquitination and consequent proteasomal degradation of the POI. Notably, one major issue in TPD is the lack of ligandable E3 ligases, as current studies predominantly use CUL4CRBN and CUL2VHL. The TPD community is seeking to expand the landscape of ligandable E3 ligases, but most discoveries rely on phenotypic screens or serendipity, necessitating systematic target deconvolution. Here, we examine and discuss both current and emerging E3 ligase deconvolution approaches for degraders discovered from phenotypic screens or monovalent glue chemistry campaigns, highlighting future prospects for identifying more ligandable E3 ligases.
Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Jiayi Lin,Jinmei Jin,Yiwen Shen,Lijun Zhang,Gang Gong,Huiting Bian,Hongzhuan Chen,Dale G. Nagle,Ye Wu,Weidong Zhang,Xin Luan

DOI: https://doi.org/10.7150/thno.62686

IF: 11.6

2021-01-01

Theranostics

Abstract:Classic small molecule inhibitors that directly target pathogenic proteins typically rely on the accessible binding sites to achieve prolonged occupancy and influence protein functions. The emerging targeted protein degradation (TPD) strategies exemplified by PROteolysis TArgeting Chimeras (PROTACs) are revolutionizing conventional drug discovery modality to target proteins of interest (POIs) that were categorized as "undruggable" before, however, these strategies are limited within intracellular POIs. The novel new degrader technologies such as LYsosome-TArgeting Chimaeras (LYTACs) and Antibody-based PROTACs (AbTACs) have been successfully developed to expand the scope of TPD to extracellular and membrane proteins, fulfilling huge unmet medical needs. Here, we systematically review the currently viable protein degradation strategies, emphasize that LYTACs and AbTACs turn a new avenue for the development of TPD, and highlight the potential challenges and directions in this vibrant field.

medicine, research & experimental
Targeted protein degradation: mechanisms, strategies and application

Lin Zhao,Jia Zhao,Kunhong Zhong,Aiping Tong,Da Jia

DOI: https://doi.org/10.1038/s41392-022-00966-4

IF: 39.3

2022-04-04

Signal Transduction and Targeted Therapy

Abstract:Abstract Traditional drug discovery mainly focuses on direct regulation of protein activity. The development and application of protein activity modulators, particularly inhibitors, has been the mainstream in drug development. In recent years, PROteolysis TArgeting Chimeras (PROTAC) technology has emerged as one of the most promising approaches to remove specific disease-associated proteins by exploiting cells’ own destruction machinery. In addition to PROTAC, many different targeted protein degradation (TPD) strategies including, but not limited to, molecular glue, Lysosome-Targeting Chimaera (LYTAC), and Antibody-based PROTAC (AbTAC), are emerging. These technologies have not only greatly expanded the scope of TPD, but also provided fresh insights into drug discovery. Here, we summarize recent advances of major TPD technologies, discuss their potential applications, and hope to provide a prime for both biologists and chemists who are interested in this vibrant field.

biochemistry & molecular biology,cell biology
PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Si-Min Qi,Jinyun Dong,Zhi-Yuan Xu,Xiang-Dong Cheng,Wei-Dong Zhang,Jiang-Jiang Qin

DOI: https://doi.org/10.3389/fphar.2021.692574

IF: 5.6

2021-05-07

Frontiers in Pharmacology

Abstract:Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein degradation tool developed in recent years that can ubiquitinate the target proteins through the ubiquitin-proteasome system (UPS) to achieve an effect on tumor growth. A number of literature studies on PROTAC technology have proved an insight into the feasibility of PROTAC technology to degrade target proteins. Additionally, the first oral PROTACs (ARV-110 and ARV-471) have shown encouraging results in clinical trials for prostate and breast cancer treatment, which inspires a greater enthusiasm for PROTAC research. Here we focus on the structures and mechanisms of PROTACs and describe several classes of effective PROTAC degraders based on E3 ligases.

pharmacology & pharmacy
Advancing targeted protein degradation for metabolic diseases therapy

Qian-Qian Zhou,Hai-Tao Xiao,Fan Yang,Yong-Dan Wang,Ping Li,Zu-Guo Zheng

DOI: https://doi.org/10.1016/j.phrs.2022.106627

Abstract:The development and application of traditional drugs represented by small molecule chemical drugs and biological agents, especially inhibitors, have become the mainstream drug development. In recent years, targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cell self-destruction mechanisms. Many different TPD strategies are emerging based on the ubiquitin-proteasome system (UPS) and the autophagy-lysosomal pathway (ALP), including but not limited to proteolysis-targeting chimeras (PROTAC), molecular glues (MG), lysosome targeting chimeras (LYTAC), chaperone-mediated autophagy (CMA)-targeting chimeras, autophagy-targeting chimera (AUTAC), autophagosome-tethering compound (ATTEC), and autophagy-targeting chimera (AUTOTAC). The advent of targeted degradation technology can change most protein targets in human cells from undruggable to druggable, greatly expanding the therapeutic prospect of refractory diseases such as metabolic syndrome. Here, we summarize the latest progress of major TPD technologies, especially in metabolic syndrome and look forward to providing new insights for drug discovery.
PROTAC targeted protein degraders: the past is prologue

Miklós Békés,David R. Langley,Craig M. Crews

DOI: https://doi.org/10.1038/s41573-021-00371-6

IF: 112.288

2022-01-18

Nature Reviews Drug Discovery

Abstract:Targeted protein degradation (TPD) is an emerging therapeutic modality with the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. In the 20 years since the concept of a proteolysis-targeting chimera (PROTAC) molecule harnessing the ubiquitin–proteasome system to degrade a target protein was reported, TPD has moved from academia to industry, where numerous companies have disclosed programmes in preclinical and early clinical development. With clinical proof-of-concept for PROTAC molecules against two well-established cancer targets provided in 2020, the field is poised to pursue targets that were previously considered ‘undruggable’. In this Review, we summarize the first two decades of PROTAC discovery and assess the current landscape, with a focus on industry activity. We then discuss key areas for the future of TPD, including establishing the target classes for which TPD is most suitable, expanding the use of ubiquitin ligases to enable precision medicine and extending the modality beyond oncology.

pharmacology & pharmacy,biotechnology & applied microbiology
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies

Xiaopeng Peng,Zhihao Hu,Limei Zeng,Meizhu Zhang,Congcong Xu,Benyan Lu,Chengpeng Tao,Weiming Chen,Wen Hou,Kui Cheng,Huichang Bi,Wanyi Pan,Jianjun Chen

DOI: https://doi.org/10.1016/j.apsb.2023.09.003

IF: 14.903

2023-09-14

Acta Pharmaceutica Sinica B

Abstract:Epigenetic pathways play a critical role in the initiation, progression, and metastasis of cancer. Over the past few decades, significant progress has been made in the development of targeted epigenetic modulators ( e.g., inhibitors). However, epigenetic inhibitors have faced multiple challenges, including limited clinical efficacy, toxicities, lack of subtype selectivity, and drug resistance. As a result, the design of new epigenetic modulators ( e.g., degraders) such as PROTACs, molecular glue, and hydrophobic tagging (HyT) degraders has garnered significant attention from both academia and pharmaceutical industry, and numerous epigenetic degraders have been discovered in the past decade. In this review, we aim to provide an in-depth illustration of new degrading strategies (2017‒2023) targeting epigenetic proteins for cancer therapy, focusing on the rational design, pharmacodynamics, pharmacokinetics, clinical status, and crystal structure information of these degraders. Importantly, we also provide deep insights into the potential challenges and corresponding remedies of this approach to drug design and development. Overall, we hope this review will offer a better mechanistic understanding and serve as a useful guide for the development of emerging epigenetic-targeting degraders.

pharmacology & pharmacy
Protein degraders enter the clinic — a new approach to cancer therapy

Deborah Chirnomas,Keith R. Hornberger,Craig M. Crews

DOI: https://doi.org/10.1038/s41571-023-00736-3

IF: 78.8

2023-02-16

Nature Reviews Clinical Oncology

Abstract:Heterobifunctional protein degraders, such as PROteolysis TArgeting Chimera (PROTAC) protein degraders, constitute a novel therapeutic modality that harnesses the cell's natural protein-degradation machinery — that is, the ubiquitin–proteasome system — to selectively target proteins involved in disease pathogenesis for elimination. Protein degraders have several potential advantages over small-molecule inhibitors that have traditionally been used for cancer treatment, including their event-driven (rather than occupancy-driven) pharmacology, which permits sub-stoichiometric drug concentrations for activity, their capacity to act iteratively and target multiple copies of a protein of interest, and their potential to target nonenzymatic proteins that were previously considered 'undruggable'. Following numerous innovations in protein degrader design and rigorous evaluation in preclinical models, protein degraders entered clinical testing in 2019. Currently, 18 protein degraders are in phase I or phase I/II clinical trials that involve patients with various tumour types, with a phase III trial of one initiated in 2022. The first safety, efficacy and pharmacokinetic data from these studies are now materializing and, although considerably more evidence is needed, protein degraders are showing promising activity as cancer therapies. Herein, we review advances in protein degrader development, the preclinical research that supported their entry into clinical studies, the available data for protein degraders in patients and future directions for this new class of drugs.

oncology

[Incomplete and complete "fetal alcohol syndrome" in three children of an alcoholic mother].

Targeted protein degrader development for cancer: advances, challenges, and opportunities

Advancing targeted protein degradation for cancer therapy

Progress of small molecules for targeted protein degradation: PROTACs and other technologies

Targeted protein degradation in cancers: Orthodox PROTACs and beyond

Recent advances in targeted protein degraders as potential therapeutic agents

Powering up targeted protein degradation through active and passive tumour-targeting strategies: Current and future scopes

Targeted protein degradation in drug development: Recent advances and future challenges

Targeted protein degradation: advances in drug discovery and clinical practice

World Medical Association ;now more realistic' in dealing with problems.

Hydrophobic tag-based protein degradation: Development, opportunity and challenge

Novel approaches to targeted protein degradation technologies in drug discovery

Recent progress in degradation of membrane proteins by PROTACs and alternative targeted protein degradation techniques

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins

Targeted protein degradation: mechanisms, strategies and application

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

Advancing targeted protein degradation for metabolic diseases therapy

PROTAC targeted protein degraders: the past is prologue

Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies

Protein degraders enter the clinic — a new approach to cancer therapy